June 6, 2016Journal of Clinical Oncology1,016 citationsOpen Access
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.